Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test

Journal of Clinical Microbiology

Volumn 45, Issue 11, 2007, Pages 3821-3823

  Coutlée, François ^a,b,c   Rouleau, Danielle ^a,b   Ghattas, Georges ^a   Hankins, Catherine ^c,d   Vézina, Sylvie ^e   Coté, Pierre ^f   Macleod, John ^c   De Pokomandy, Alexandra ^a   Money, Deborah ^g   Walmsley, Sharon ^h   Voyer, Hélène ^a   Brassard, Paul ^c   Franco, Eduardo ^c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^e Clinique Medicale l'Actuel   (Canada)

^f Clinique Medicale du Quartier Latin   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E6; VIRUS DNA;

ANUS; ARTICLE; DNA DETERMINATION; FEMALE; GENE SEQUENCE; GENITAL SYSTEM; GENOTYPE; HUMAN; HYBRIDIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; VERRUCA VULGARIS; WART VIRUS; WART VIRUS 52;

ANAL CANAL; DNA, VIRAL; FEMALE; GENITALIA; GENOTYPE; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 52;

EID: 36349020906     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01145-07     Document Type: Article

References (18)

1. Aho, J., C. Hankins, C. Tremblay, F. Lang, P. Forest, K. Pourreaux, F. Rouah, The Canadian Women's HIV Study Group, and F. Coutlée. 2003. Molecular analysis of human papillomavirus type 52 isolates detected in the genital tract of HIV-seropositive and seronegative women. J. Infect. Dis. 188:1517-1527.
2. Castle, P. E., D. Solomon, M. Schiffman, and C. M. Wheeler. 2005. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl. Cancer Inst. 97:1066-1071.
3. Clifford, G. M., S. Gallus, R. Herrero, N. Munoz, P. J. Snijders, S. Vaccarella, P. T. Ann, C. Ferreccio, N. T. Hieu, E. Mates, M. Molano, R. Rajkumar, G. Ronco, S. de-Sanjose, H. R. Shin, S. Sukvirach, J. O. Thomas, S. Tunsakul, C. J. Meijer, and S. Franceschi. 2005. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on CancerHPV prevalence surveys: a pooled analysis. Lancet 366:991-998.
4. Clifford, G. M., R. K. Rana, S. Franceschi, J. S. Smith, G. Gough, and J. M. Pimenta. 2005. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol. Biomarkers Prev. 14:1157-1164.
5. Clifford, G. M., J. S. Smith, M. Plummer, N. Munoz, and S. Franceschi. 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88:63-73.
6. Coutlée, F., P. Gravitt, H. Richardson, C. Hankins, E. Franco, N. Lapointe, H. Voyer, and The Canadian Women's HIV Study Group. 1999. Nonisotopic detection and typing of human papillomavirus DNA in genital samples by the line blot assay. J. Clin. Microbiol. 37:1852-1857.
7. Coutlée, F., P. Gravitt, J. Kornegay, C. Hankins, H. Richardson, J. R. Lapointe, H. Voyer, The Canadian Women's HIV Study Group, and E. L. Franco. 2002. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J. Clin. Microbiol. 40:902-907.
8. Coutlee, F., D. Rouleau, P. Petignat, G. Ghattas, J. Kornegay, P. Schlagg, S. Boyle, C. Hankins, D. Vézina, P. Cote, J. Macleod, H. Voyer, P. Forest, S. Walmsley, and E. L. Franco. 2006. Enhanced detection and typing of human papillomavirus DNA in anogenital samples with PGMY primers and the Linear Array HPV genotyping test. J. Clin. Microbiol. 44:1998-2006.
9. Ferenczy, A., and E. L. Franco. 2002. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 3:11-16.
10. Gravitt, P., C. L. Peyton, T. Q. Alessi, C. Wheeler, F. Coutlée, A. Hildesheim, M. Schiffman, D. R. Scott, and R. J. Apple. 2000. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 38:357-361.
11. Hankins, C., F. Coutlee, N. Lapointe, P. Simard, T. Tran, J. Samson, L. Hum, and The Canadian Women's HIV Study Group. 1999. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Can. Med. Assoc. J. 160:185-191.
12. Herrero, R., P. E. Castle, M. Schiffman, M. C. Bratti, A. Hildesheim, J. Morales, M. Alfaro, M. E. Sherman, S. Wacholder, S. Chen, A. C. Rodriguez, and R. D. Burk. 2005. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J. Infect. Dis. 191:1796-1807.
13. Khan, M. J., P. E. Castle, A. T. Lorincz, S. Wacholder, M. Sherman, D. R. Scott, B. B. Rush, A. G. Glass, and M. Schiffman. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97:1072-1079.
14. Koushik, A., A. Ghosh, E. Duarte-Franco, P. Forest, H. Voyer, G. Matlashewski, F. Coutlee, and E. L. Franco. 2005. The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Det. Prev. 29:307-316.
15. Meijer, C. J., P. J. Snijders, and P. E. Castle. 2006. Clinical utility of HPV genotyping. Gynecol. Oncol. 103:12-17.
16. Petignat, P., C. Hankins, S. Walmsley, D. Money, D. Provencher, K. Pourreaux, J. Kornegay, F. Rouah, and F. Coutlee. 2005. Self-sampling is associated with increased detection of human papillomavirus DNA in the genital tract of HIV-seropositive women. Clin. Infect. Dis. 41:527-534.
17. Whiley, D. M., and T. P. Sloots. 2005. Sequence variation in primer targets affects the accuracy of viral quantitative PCR. J. Clin. Virol. 34:104-107.
18. Wright, T. C. J., M. Schiffman, D. Solomon, J. T. Cox, F. Garcia, S. Goldie, K. Hatch, K. L. Noller, N. Roach, C. Runowicz, and D. Saslow. 2004. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet. Gynecol. 103:304-309.